A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects With Primary Biliary Cholangitis
Latest Information Update: 03 Oct 2025
At a glance
- Drugs Bezafibrate/obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Intercept Pharmaceuticals
Most Recent Events
- 25 Sep 2025 Planned End Date changed from 1 Mar 2030 to 1 Oct 2025.
- 25 Sep 2025 Planned primary completion date changed from 1 Jan 2029 to 1 Oct 2025.
- 25 Sep 2025 Status changed from recruiting to active, no longer recruiting.